by Truveta staff | Sep 11, 2024 | Research
The overall trends of hospitalizations associated with viral gastroenteritis – norovirus and rotavirus – show a steady decrease over the last few months, leading to a rate of 0.04% in August 2024 in the overall population. However, we see first indicators that the...
by Truveta Research | Aug 23, 2024 | Research, Research Insights
Authors: Charlotte Baker DrPH MPH CPH ⊕Truveta, Inc, Bellevue, WA, Brianna M. Goodwin Cartwright ⊕Truveta, Inc, Bellevue, WA, Patricia J. Rodriguez, PhD MPH ⊕Truveta, Inc, Bellevue, WA, Samuel Gratzl PhD ⊕Truveta, Inc, Bellevue, WA, Nicholas Stucky, MD PhD ⊕Truveta,...
by Truveta staff | Aug 15, 2024 | Data
Psoriasis is more than just a skin condition – it’s a chronic, systemic disease that affects over 8 million people in the United States, profoundly impacting their quality of life. As a complex, immune-mediated disease, psoriasis presents a variety of challenges to...
by Truveta Research | Jul 25, 2024 | Research, Research Insights
The analysis was based on a sample of 17,501,982 patients from January 2018 to May 2024. During the study period, 9,271 patients were tested (using CPT code 93922) for the first time and had a diagnosis of peripheral vascular disease/peripheral artery disease...
by Truveta Research | Jul 8, 2024 | Research
Truveta Research’s comparative effectiveness study exploring weight loss among patients taking semaglutide (Ozempic) and tirzepatide (Mounjaro) has been published in JAMA Internal Medicine. Glucagon-like peptide 1 receptor agonist-based (GLP-1 RA) medications,...
